GDC-1261 Safety and Activity in Advanced Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This early-stage trial tests a new drug called GDC-1261 in men with advanced prostate cancer that has spread or gotten worse despite previous treatment. The study will look at whether the drug is safe and whether it helps slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that has spread to other parts of your body (metastatic disease)
- Your cancer has progressed despite your most recent cancer treatment
- You are taking hormone-blocking therapy (androgen deprivation therapy) or have had both testicles surgically removed
- You are generally healthy enough for treatment, with good organ function and life expectancy of at least 3 months
- You have not received other cancer-fighting drugs in the past 14 days
- You do not have untreated cancer in your brain or spinal cord, uncontrolled pain, or an active infection requiring antibiotics
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests two new investigational drugs, JANX013 and JANX007, together in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination is safe and effective.
This study tests an experimental drug, alone or with other treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if it can shrink tumors or slow the disease.
This trial tests a new drug called INV-9956 in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. It aims to see if the drug is safe and effective.
This trial tests an experimental new drug (GSK5471713) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It is for people who have already tried certain hormone treatments and chemotherapy.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.